Summary:
A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL taken Daily at Bedtime in Patients with Military-Related PTSD
Qualified Participants Must:
• Be between 18 and 75 years old
•
PTSD has to have occurred from military service post 2001
Qualified Participants May Receive:
Compensation for time and travel, additional compensation for pre-screen and visits. Participants may also receive study investigational medication or placebo.